Inclusion Criteria:

•Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
•Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/002 .
•A male or female subject, recruited 10 years (+/
• 9 months) after booster vaccination in study 263855/002.
•Healthy subjects as established by medical history and clinical examination before entering into the study.
•If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of booster vaccination.
•Written informed consent obtained from the subject.



Exclusion Criteria:

•Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
•Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
•Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
•Previous booster vaccination against diphtheria, tetanus or pertussis since the last dose received in study 263855/002
•History of diphtheria, tetanus, or pertussis diseases.
•Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination
•History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
•Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
•Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
•Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :- hypersensitivity reaction to any component of the vaccine; - encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; - fever ≥ 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause; - collapse or shock-like state within 48 hours of vaccination; - convulsions with or without fever, occurring within 3 days of vaccination.
•Acute disease at the time of enrolment.
•Pregnant or lactating female.
•Female planning to become pregnant or planning to discontinue contraceptive precautions.

• Australia (click to view all sites in Australia)
• GSK Investigational Site
  Westmead, New South Wales, 2145; Completed;